NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q4 2022
Institutional positions in NewAmsterdam Pharma Co N.V. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +14 vs. Q3 2022
- Shares held
- 33.5M
- +33.5M vs. Q3 2022
- Total value
- $362.2M
- +$362.2M vs. Q3 2022
- New holders
- 14
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DuPont Capital Management Corp | 1 | $11 | 0.00% | +1 | New |
| Tower Research Capital LLC (TRC) | 88 | $1.00K | 0.00% | +88 | New |
| JPMorgan Chase & Co | 1,102 | $12.0K | 0.00% | +1,102 | New |
| Alyeska Investment Group, L.P. | 200,000 | $1.89M | 0.02% | +200,000 | New |
| Ensign Peak Advisors, Inc | 355,000 | $3.87M | 0.01% | +355,000 | New |
| Janus Henderson Group PLC | 563,119 | $5.33M | 0.00% | +563,119 | New |
| GMT Capital Corp | 1,000,000 | $10.9M | 0.50% | +1,000,000 | New |
| BVF Inc | 1,521,948 | $16.0M | 0.68% | +1,521,948 | New |
| Medicxi Ventures Management (Jersey) Ltd | 2,000,000 | $21.8M | 9.16% | +2,000,000 | New |
| Deerfield Management Company, L.P. (Series C) | 2,480,199 | $27.0M | 0.56% | +2,480,199 | New |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,753,828 | $39.5M | 0.20% | +3,753,828 | New |
| Ra Capital Management, L.P. | 4,000,000 | $43.6M | 0.88% | +4,000,000 | New |
| Bain Capital Life Sciences Investors, LLC | 8,300,000 | $90.5M | 10.11% | +8,300,000 | New |
| Frazier Life Sciences Management, L.P. | 9,341,551 | $101.8M | 6.33% | +9,341,551 | New |